

MEDIA RELEASE

Saiba Animal Health AG enters into an Agreement with Boehringer Ingelheim

Pfäffikon (SZ) Switzerland 9th of December 2020 – Saiba Animal Health reported today that it has executed a contract with Boehringer Ingelheim.

Saiba Animal Health AG announced Wednesday the commencement of an agreement with Boehringer Ingelheim, a global leader in animal health. The new partnership will further enable a core element of Saiba's business strategy, which is to form alliances with top-tier companies in order to advance its technology, projects and pipeline. Towards this end, the agreement announced today is the fourth with an industry leader since Saiba's founding in 2014.

Dr Gary T. Jennings, CEO of Saiba Animal Health AG stated, "We are delighted to have signed this agreement with Boehringer, and honored to be working with such a renowned and innovative global player in the expanding and lucrative animal health sector. Boehringer Ingelheim's expertise and strength in development and marketing makes them an ideal partner for us. Moreover, we feel that partnership with a company of such stature validates the potential of our technology to address major unmet needs in veterinary medicine"

For further information, please contact

Saiba Animal Health AG
CH-8808 Pfäffikon (SZ),
Switzerland
Gary Jennings, PhD
CEO
gary.jennings@saiba-animalhealth.com
Website <https://www.saiba-animalhealth.com>

About Saiba Animal Health AG

Saiba Animal Health AG is a privately held Swiss biotechnology company headquartered in Pfäffikon (SZ), Switzerland that was formed as a spin-off company from the University of Zürich in 2013. Saiba Animal Health was formerly known as HypoPet AG until it implemented a name change in October 2020. The company is developing therapeutic virus-like particle (VLP) vaccines designed to instruct the patient's immune system to produce antibodies, which specifically neutralize disease-associated molecules within the animal and thereby modulate chronic disease processes. Taking advantage of the flexibility of its platform VLP vaccine technology, Saiba Animal Health AG is establishing a high-quality pipeline filled with promising new animal drug candidates that address major unmet needs in veterinary medicine. The remarkable advances achieved in the treatment of chronic human diseases by the use of monoclonal antibodies can now be made available to our pets by the use of pet-specific vaccines. Saiba Animal Health AG is leveraging the experience of monoclonal antibodies, which have already achieved proof of principle (efficacy, safety & commercial) in humans and in some cases in companion animals. Saiba Animal Health's VLP platforms are also used to develop vaccines against infectious diseases.

About Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Forward looking statement

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Saiba Animal Health AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.